Published in Clin Nucl Med on March 01, 2014
Pretreatment (18)F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma--a retrospective study. Radiat Oncol (2015) 0.87
Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? Clin Nucl Med (2015) 0.80
Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg (2015) 0.79
Practical no-gold-standard evaluation framework for quantitative imaging methods: application to lesion segmentation in positron emission tomography. J Med Imaging (Bellingham) (2017) 0.76
Imaging modality utilization trends in patients with stage III-IV oropharyngeal squamous cell carcinoma. Am J Nucl Med Mol Imaging (2015) 0.76
Race disparities attributed to volumetric tumor burden in patients with head and neck cancer treated with radiotherapy. Head Neck (2015) 0.75
Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer. BMC Cancer (2016) 0.75
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer (2004) 2.59
Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res (2009) 2.12
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol (2008) 1.97
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med (2012) 1.57
FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg (2004) 1.51
18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med (2012) 1.32
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med (2012) 1.32
Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol (2009) 1.17
Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys (2011) 1.17
Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med (2012) 1.10
The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol (2011) 1.10
Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR Am J Neuroradiol (2009) 1.08
Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck (2009) 1.07
Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. AJR Am J Roentgenol (2011) 0.97
Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol (2009) 0.97
Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging (2012) 0.96
Clinical features of HPV-related head and neck squamous cell carcinoma: presentation and work-up. Otolaryngol Clin North Am (2012) 0.94
Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Ann Surg Oncol (2009) 0.91
Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology (2010) 0.90
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38
Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation (2005) 3.33
Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med (2003) 3.15
Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med (2004) 3.00
Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med (2003) 2.61
"USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med (2003) 2.45
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis (2007) 2.42
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 2.36
Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. J Am Coll Cardiol (2008) 2.33
Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2010) 2.31
Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg (2007) 2.28
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. Head Neck (2012) 2.07
Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med (2011) 1.95
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med (2003) 1.95
Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res (2009) 1.89
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. J Nucl Med (2005) 1.83
Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys (2009) 1.83
18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med (2007) 1.79
Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol (2003) 1.74
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med (2005) 1.72
Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol (2005) 1.71
CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med (2010) 1.70
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med (2003) 1.64
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med (2012) 1.62
Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. J Nucl Cardiol (2007) 1.62
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology (2005) 1.61
Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol (2002) 1.59
18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med (2012) 1.57
Comparison of uptake of multiple clinical radiotracers into brown adipose tissue under cold-stimulated and nonstimulated conditions. J Nucl Med (2007) 1.56
Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys (2007) 1.55
Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med (2009) 1.54
Malignant odontogenic tumors: a 22-year experience. Laryngoscope (2004) 1.53
18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med (2009) 1.53
Noninvasive diffuse optical measurement of blood flow and blood oxygenation for monitoring radiation therapy in patients with head and neck tumors: a pilot study. J Biomed Opt (2007) 1.51
Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Nucl Med Mol Imaging (2014) 1.51
Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology (2011) 1.48
Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer (2005) 1.45
ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncol (2011) 1.45
Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control. Arch Otolaryngol Head Neck Surg (2012) 1.44
Transoral robotic surgery for parapharyngeal space tumors. ORL J Otorhinolaryngol Relat Spec (2010) 1.43
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. J Nucl Med (2002) 1.42
Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. J Comput Assist Tomogr (2007) 1.38
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One (2009) 1.37
PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med (2002) 1.37
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.35
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Transoral robotic surgery and human papillomavirus status: Oncologic results. Head Neck (2010) 1.33
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med (2012) 1.32
Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology (2003) 1.28
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med (2009) 1.27
Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck (2011) 1.26
Transoral robotic surgery: does the ends justify the means? Curr Opin Otolaryngol Head Neck Surg (2009) 1.26
KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer (2010) 1.26
124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med (2009) 1.25
FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging (2002) 1.25
Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. Eur J Nucl Med Mol Imaging (2003) 1.25
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med (2007) 1.24
Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol (2002) 1.23
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck. AJR Am J Roentgenol (2013) 1.21
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging (2005) 1.20
Mitochondrial DNA content increase in response to cigarette smoking. Cancer Epidemiol Biomarkers Prev (2006) 1.20
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med (2007) 1.19
Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: a subset analysis of the University of Pennsylvania transoral robotic surgery trial. Laryngoscope (2010) 1.18
Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology (2005) 1.17
Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer Res (2003) 1.16
Effect of nicotine and ephedrine on the accumulation of 18F-FDG in brown adipose tissue. J Nucl Med (2007) 1.15
Brachial plexus contouring with CT and MR imaging in radiation therapy planning for head and neck cancer. Radiographics (2010) 1.15
Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck. J Magn Reson Imaging (2007) 1.14
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med (2006) 1.14
Tumor response assessment is more robust with sequential CT scanning than external caliper measurements. Acad Radiol (2005) 1.14
Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg (2006) 1.14
Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med (2006) 1.12
Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys (2008) 1.12
Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant (2009) 1.10
Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med (2012) 1.10
CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology (2005) 1.10
Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer (2004) 1.09
Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg (2007) 1.09
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med (2007) 1.08
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol (2005) 1.08
Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol (2003) 1.08
Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? J Clin Oncol (2013) 1.06
Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med (2009) 1.05
Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med (2006) 1.05
Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res (2011) 1.04
Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res (2005) 1.04
Clinically significant abnormal findings on the "nondiagnostic" CT portion of low-amperage-CT attenuation-corrected myocardial perfusion SPECT/CT studies. J Nucl Med (2006) 1.04
Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med (2007) 1.03
The added diagnostic value of liquid gastric emptying compared with solid emptying alone. J Nucl Med (2009) 1.03